↓ Skip to main content

B Cell Receptor Signaling

Overview of attention for book
Attention for Chapter 484: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
77 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Chapter number 484
Book title
B Cell Receptor Signaling
Published in
Current topics in microbiology and immunology, September 2015
DOI 10.1007/82_2015_484
Pubmed ID
Book ISBNs
978-3-31-926131-7, 978-3-31-926133-1
Authors

Okkenhaug, Klaus, Burger, Jan A, Burger, Jan A., Klaus Okkenhaug, Jan A. Burger

Abstract

B cells provide immunity to extracellular pathogens by secreting a diverse repertoire of antibodies with high affinity and specificity for exposed antigens. The B cell receptor (BCR ) is a transmembrane antibody, which facilitates the clonal selection of B cells producing secreted antibodies of the same specificity. The diverse antibody repertoire is generated by V(D)J recombination of heavy and light chain genes, whereas affinity maturation is mediated by activation-induced cytidine deaminase (AID)-mediated mutagenesis. These processes, which are essential for the generation of adaptive humoral immunity, also render B cells susceptible to chromosomal rearrangements and point mutations that in some cases lead to cancer. In this chapter, we will review the central role of PI3K s in mediating signals from the B cell receptor that not only facilitate the development of functional B cell repertoire, but also support the growth and survival of neoplastic B cells, focusing on chronic lymphocytic leukemia (CLL ) B cells. Perhaps because of the central role played by PI3K in BCR signaling, B cell leukemia and lymphomas are the first diseases for which a PI3K inhibitor has been approved for clinical use.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Ireland 1 1%
Unknown 74 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 18%
Student > Master 10 13%
Researcher 8 10%
Student > Bachelor 7 9%
Other 7 9%
Other 16 21%
Unknown 15 19%
Readers by discipline Count As %
Medicine and Dentistry 17 22%
Biochemistry, Genetics and Molecular Biology 15 19%
Agricultural and Biological Sciences 13 17%
Immunology and Microbiology 7 9%
Chemistry 3 4%
Other 7 9%
Unknown 15 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2015.
All research outputs
#16,599,928
of 26,184,649 outputs
Outputs from Current topics in microbiology and immunology
#419
of 715 outputs
Outputs of similar age
#150,966
of 281,470 outputs
Outputs of similar age from Current topics in microbiology and immunology
#11
of 23 outputs
Altmetric has tracked 26,184,649 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 715 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,470 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.